Immunovaccine (TSX-V: IMV) is a clinical stage biotechnology company developing infectious disease and therapeutic cancer vaccines for human health. The company continues to strengthen its vaccine pipeline through licensing and strategic partnering. With positive clinical safety data and recent partnerships with LIAI, NIH, Defence Research & Development Canada, and NCI the value of their Depovax™ vaccine delivery system has been significantly enhanced.
For more information pleae visit the company website at: www.imvaccine.com
The following information is required to view this webcast.
Please complete all the information to continue.